Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan Plus Fulvestrant in ER+/HER2- Metastatic Breast Cancer (LITESPARK-029)
NCT06428396Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of belzutifan in breast cancer, sponsored by Merck & Co.. Started Nov 2024; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06428396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428396.